F. Hernandez Gonzalez (Barcelona, Spain), G. Sgalla (Rome, Italy)
Humoral Response among patients with Interstitial Lung Disease Vaccinated with the BNT162b2 SARS-Cov-2 vaccine - a prospective cohort study
B. Pertzov (Raanana, Israel), E. Shmueli (Raanana, Israel), H. Ben Zvi (Raanana, Israel), A. Massarweh (Raanana, Israel), T. Barkan (Raanana, Israel), A. Ness (Raanana, Israel), Y. Shostak (Raanana, Israel), L. Freidkin (Raanana, Israel), O. Shtraichman (Raanana, Israel), M. Kramer (Raanana, Israel)
|  |
SARS-CoV2 vaccination in Hungarian IPF patients
N. Toth (Budapest, Hungary), T. Nagy (Budapest, Hungary), E. Barczi (Budapest, Hungary), A. Nagy (Budapest, Hungary), N. Eszes (Budapest, Hungary), A. Bohacs (Budapest, Hungary), K. Vincze (Budapest, Hungary), V. Müller (Budapest, Hungary)
|  |
INFLUENCE OF ATMOSPHERIC POLLUTION IN MADRID ON THE SEVERITY OF NON-IPF ILD
P. Mariscal Aguilar (Madrid, Spain), L. Gómez Carrera (Madrid, Spain), C. Carpio Segura (Madrid, Spain), G. Bonilla Hernán (Madrid, Spain), M. Torres Sánchez (Madrid, Spain), M. Fernández Velilla-Peña (Madrid, Spain), E. Villamañán Bueno (Madrid, Spain), R. Regojo Zapata (Madrid, Spain), J. Pavón Guede (Madrid, Spain), C. Prados Sánchez (Madrid, Spain), R. Álvarez-Sala Walther (Madrid, Spain)
| |
Defining stakeholders’ research priorities in progressive pulmonary fibrosis in the United Kingdom
L. Fabbri (ret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, Division of Respiratory Medicine, University of Nottingham, Nottingham Biomedical Research Centre, National Institute for Health ResearchLondon, United Kingdom), L. Wright (Peterborough, United Kingdom), S. Jones (Peterborough, United Kingdom), W. Adams (Peterborough, United Kingdom), K. Cowan (Southampton, United Kingdom), S. Hart (York, United Kingdom), A. Russell (Exeter, United Kingdom), M. Gibbons (Exeter, United Kingdom), N. Chaudhuri (Belfast, United Kingdom), J. Lynch-Wilson (Carmarthen, United Kingdom), G. Jenkins (London, United Kingdom)
| |
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF
T. Karampitsakos (Patras, Greece), O. Papaioannou (Patras, Greece), I. Dimeas (Larissa, Greece), P. Tsiri (Patras, Greece), V. Sotiropoulou (Patras, Greece), I. Tomos (Athens, Greece), I. Papanikolaou (Corfu, Greece), M. Katsaras (Patras, Greece), P. Kirgou (Larissa, Greece), Z. Daniil (Larissa, Greece), K. Gourgoulianis (Larissa, Greece), D. Papalexatos (Patras, Greece), F. Sampsonas (Patras, Greece), E. Manali (Athens, Greece), S. Papiris (Athens, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Patras, Greece)
| |
Early administration of nintedanib after the onset of acute exacerbation in patients with interstitial lung disease
M. Kato (Tokyo, Japan), S. Sasaki (Tokyo, Japan), E. Hayakawa (Tokyo, Japan), S. Soma (Tokyo, Japan), Y. Arai (Tokyo, Japan), S. Nakazawa (Tokyo, Japan), H. Motomura (Tokyo, Japan), I. Sumiyoshi (Tokyo, Japan), Y. Ochi (Tokyo, Japan), K. Kadoya (Tokyo, Japan), S. Togo (Tokyo, Japan), K. Takahashi (Tokyo, Japan)
| |
Improved survival of IPF patients treated with antifibrotic drugs compared with untreated patients
M. Platenburg (Nieuwegein, Netherlands), C. Van Moorsel (Nieuwegein, Netherlands), I. Wiertz (Nieuwegein, Netherlands), P. Zanen (Nieuwegein, Netherlands), J. Van Der Vis (Nieuwegein, Netherlands), A. Vorselaars (Nieuwegein, Netherlands), M. Veltkamp (Nieuwegein, Netherlands), J. Grutters (Nieuwegein, Netherlands)
| |
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
E. Åttingsberg (København , Denmark), N. Hoyer (København , Denmark), S. Shaker (København , Denmark)
| |
Real-world outcomes for incidental interstitial lung abnormalities diagnosed over the baseline round of the Yorkshire Lung Screening Trial.
S. Upperton (Leeds, United Kingdom), C. Bradley (Craigavon, United Kingdom), P. Beirne (Leeds, United Kingdom), B. Bhartia (Leeds, United Kingdom), A. Boland (Leeds, United Kingdom), P. Crosbie (Manchester, United Kingdom), M. Darby (Leeds, United Kingdom), R. Gabe (London, United Kingdom), M. Kennedy (Leeds, United Kingdom), T. Sutherland (Leeds, United Kingdom), M. Callister (Leeds, United Kingdom)
| |
Comparison of three dyspnea questionnaires in predicting survival of interstitial lung diseases
O. Moran Mendoza (Kingston (ON), Canada), A. Moran Macdonald (Kingston (ON), Canada), S. Alyami (Riyadh, Saudi Arabia), M. Kish (Toronto, Canada), S. Davison (Toronto, Canada)
| |
Long-term effect of nintedanib treatment in 11 countries of Europe and Asia
M. Koziar Vasakova (Prague, Czech Republic), M. Sterclova (Prague, Czech Republic), N. Mogulkoc Bishop (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Kramer (Petah Tikva, Israel), M. Hajkova (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), M. Studnicka (Salzburg, Austria), J. Tekavec-Trkanjec (Zagreb, Croatia), A. Penev (Sofia, Bulgaria), P. Ovesna (Brno, Czech Republic), J. Gregor (Brno, Czech Republic)
| |
Post-hoc analysis of clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis (IPF) by elevated autoantibody (AAb) status
C. Newton (Dallas, United States), T. Kulkarni (Birmingham, United States), K. Samara (Basel, Switzerland), J. Ko (South San Francisco, United States), S. Gupta (South San Francisco, United States), E. Bernstein (New York, United States), A. Samara (Athens, Greece)
| |
Lessons learned from 4 years Multidisciplinary discussion (MDD) in interstitial lung diseases (ILD)
A. Khalifa (Wetzikon, Switzerland), G. Wiest (Hamburg, Germany), D. Kirsten (Grosshansdorf, Germany), A. Kirsten (Großhansdorf, Germany)
| |
Therapeutic decisions regarding initiation of antifibrotic therapy in IPF: a multicenter, prospective cohort study from Poland.
K. Górska (Warszawa, Poland), M. Maskey-Warzechowska (Warszawa, Poland), M. Barnas (Warszawa, Poland), A. Bialas (Lodz, Poland), A. Barczyk (Katowice, Poland), H. Jagielska-Len (Zielona Gora, Poland), E. Jassem (Gdansk, Poland), A. Kania (Cracow, Poland), K. Lewandowska (Warsaw, Poland), S. Majewski (Lodz, Poland), M. Martusewicz-Boros (Warsaw, Poland), W. Piotrowski (Lodz, Poland), A. Sieminska (Gdansk, Poland), K. Sladek (Cracow, Poland), M. Sobiecka (Warsaw, Poland), M. Trzaska-Sobczak (Katowice, Poland), W. Tomkowski (Warsaw, Poland), B. Zolnowska (Warsaw, Poland), R. Krenke (Warsaw, Poland)
| |
Patterns of antifibrotic treatment changes in a cohort of idiopathic pulmonary fibrosis patients
I. Skov (Odense N, Denmark), A. Darbrodi (Odense C, Denmark), J. Rømhild Davidsen (Odense C, Denmark)
| |
Could family history avoid lung biopsy in fibrotic interstitial lung diseases? From a clinical retrospective cohort study.
D. Duminy-Luppi (L'Hospitalet de Llobregat, Spain), A. Alcaide-Aldeano (L'Hospitalet de Llobregat, Spain), L. Planas-Cerezales (L'Hospitalet de Llobregat, Spain), G. Bermudo-Peloche (L'Hospitalet de Llobregat, Spain), V. Vicens-Zygmunt (L'Hospitalet de Llobregat, Spain), P. Luburich (L'Hospitalet de Llobregat, Spain), B. Del Rio (L'Hospitalet de Llobregat, Spain), R. Llatjós (L'Hospitalet de Llobregat, Spain), L. Pijuan (L'Hospitalet de Llobregat, Spain), I. Escobar (L'Hospitalet de Llobregat, Spain), A. Montes-Worboys (L'Hospitalet de Llobregat, Spain), Y. Gutiérrez-Rodríguez (L'Hospitalet de Llobregat, Spain), R. Perona (Madrid, Spain), S. Santos-Pérez (L'Hospitalet de Llobregat, Spain), J. Dorca (L'Hospitalet de Llobregat, Spain), M. Molina-Molina (L'Hospitalet de Llobregat, Spain)
| |
Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates
N. Hoyer (Copenhagen, Denmark), T. Prior (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), S. Shaker (Copenhagen, Denmark)
| |
Persistence, safety, and costs of antifibrotic treatment for idiopathic pulmonary fibrosis (IPF): a US Veterans Health Administration (VHA) claims study
Y. Qiu (Princeton, United States), J. Zhu (Princeton, United States), B. Elpers (Princeton, United States), C. Dieyi (Plano, United States), C. Byrne (Plano, United States), R. Singh (Plano, United States), A. Fischer (Princeton, United States)
| |
Effects of low dose pirfenidone on lung function for patients with idiopathic pulmonary fibrosis in real practice
K. Moon (Gangneung, Republic of Korea), B. Jung (Gangneung, Republic of Korea), J. Lee (Gangneung, Republic of Korea), M. Kim (Gangneung, Republic of Korea)
| |
Late Breaking Abstract - Inhaled pirfenidone is associated with better quality of life scores in idiopathic pulmonary fibrosis
G. Kim (Los Angeles, United States), J. Goldin (Los Angeles, United States), F. Woodhead (Seattle, United States), C. Thompson (Seattle, United States), M. Shaffer (Seattle, United States), K. Otto (Seattle, United States), B. Montgomery (Seattle, United States)
| |